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Background. The asialoglycoprotein receptor (ASGPR) is a hepatic receptor that mediates removal of potentially hazardous
glycoconjugates from blood in health and disease. The receptor comprises two proteins, asialoglycoprotein receptor 1 and 2
(ASGR1 and ASGR2), encoded by the genes ASGR1 and ASGR2. Design and Methods. Using reverse transcription amplification
(RT-PCR), expression of ASGR1 and ASGR2 was investigated in human peripheral blood monocytes. Results. Monocytes were
found to express ASGR1 and ASGR2 transcripts. Correctly spliced transcript variants encoding diﬀerent isoforms of ASGR1 and
ASGR2 were present in monocytes. The profile of transcript variants from both ASGR1 and ASGR2 diﬀered among individuals.
Transcript expression levels were compared with the hepatocyte cell line HepG2 which produces high levels of ASGPR. Monocyte
transcripts were 4 to 6 orders of magnitude less than in HepG2 but nonetheless readily detectable using standard RT-PCR. The
monocyte cell line THP1 gave similar results to monocytes harvested from peripheral blood, indicating it may provide a suitable
model system for studying ASGPR function in this cell type. Conclusions. Monocytes transcribe and correctly process transcripts
encoding the constituent proteins of the ASGPR. Monocytes may therefore represent a mobile pool of the receptor, capable of
reaching sites remote from the liver.
1. Introduction
The asialoglycoprotein receptor (ASGPR) (also known as the
Ashwell receptor) mediates the capture and endocytosis
of galactose- (Gal) and N-acetylgalactosamine- (GalNAc)
terminating glycoproteins. The relevance of this function has
been the subject of much debate; the primary role may be
the removal of potentially hazardous glycoconjugates arising
from normal tissue turnover, tissue injury, disease, and other
causes [1]. Studies using knock-out mice have provided
evidence for direct involvement of the ASGPR in removal of
abnormally sialylated plasma glycoproteins. Mice lacking the
sialyltransferase ST3Gal4 showed prolonged bleeding which
was attributed to ASGPR-mediated clearance of at least
one plasma hemostatic component, von Willebrand factor
(VWF), that showed decreased sialylation [2]. Findings
in mice lacking the ASGPR demonstrated that, during
sepsis, the receptor removed components of hemostasis
(VWF and platelets) that had been desialylated by bacterial
neuraminidase and thereby allowed hemostatic adaptation
that moderated disseminated intravascular coagulation and
improved host survival [3]. The ASGPR may therefore be
poised for rapid clearance of plasma glycoproteins that, for
whatever reason, show decreased or abnormal sialylation.
The highest level of expression of the ASGPR is in
the liver, in which it is located on the sinusoidal face of
hepatocytes [4]. Low-level expression has been shown in
various other cell types, such as, peritoneal macrophages in
rat [5], human intestinal epithelial cells [6], mouse testis [7],
and the rat thyroid gland [8]. The role of the receptor at these
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extrahepatic sites is uncertain. The galactosyl homeostasis
theory proposes that the balance of both Gal and GalNAc
glycoconjugates is important for normal tissue physiology
[1, 9]; whether or not expression of the ASGPR at these other
sites represents a need for localized constitutive control of
such glycoconjugates is not known.
A major area of interest focussing on the ASGPR is
the targeted gene transfer/delivery of drugs to the liver [10,
11]. For example, using GalNAc as a ligand on a siRNA-
containing complex, the latter was successfully targeted to
hepatocytes after simple intravenous injection into the tail
vein in mice [11]. Moreover, siRNA-mediated knock-down
of targeted genes was demonstrated within the hepatocytes.
Besides its potential importance in allowing liver-specific
drug targeting [12], the ASGPR is a key factor in the design
and administration of glycoprotein pharmaceuticals more
generally: the activity of the receptor can impact upon drug
half life and thereby the window of therapeutic eﬃcacy.
Human ASGPR is composed of two types of subunit: a
major subunit (asialoglycoprotein receptor 1, ASGR1) and
minor subunit (asialoglycoprotein receptor 2, ASGR2) [13].
Both subunits are type II, single pass proteins that broadly
comprise a cytoplasmic domain, transmembrane domain,
and extracellular carbohydrate recognition domain (CRD)
[14, 15]. The subunits may exist as ASGR1-ASGR2 het-
erooligomers, ASGR1homotrimers and homotetramers, and
ASGR2 homodimers and homotetramers. These diﬀerent
quaternary forms may allow for functional diﬀerences, such
as, substrate specificity or rate of endocytosis [1, 16].
The genes encoding ASGR1 and ASGR2 (ASGR1 and
ASGR2, resp.) are located on the short arm of autosome
17, approximately 58.6 kilobases (kb) apart. The genes
are evolutionarily related but diﬀer significantly in their
structural organization: ASGR1 comprises 8 exons and is
approximately 6 kb long, ASGR2 contains 9 exons occupying
13.5 kb of DNA [14, 15].
Until recently, ASGR1 was thought to yield one transcript
encoding a single protein. However, in 2010, Liu et al.
demonstrated the existence of two alternatively spliced
transcripts. The longer transcript, T1, contains all 8 exons
and is by far the more abundant; it encodes full-length
ASGR1 (isoform a, 291 aminoacids). The shorter transcript,
T2, has an in-frame deletion of exon 3 resulting in the loss of
39 residues (isoform b, 252 amino acids). Isoform b lacks the
transmembrane domain and is secreted as a soluble protein
[17].
ASGR2 gives rise to five transcripts (TH2′, T1, T2,
T3, and T4) encoding four isoforms (a to d) that contain
diﬀerent in-frame deletions arising from alternative exon
splicing events [15]. Isoforms a and c contain 5 aminoacids
that serve as a proteolysis cleavage signal near the junction
between the transmembrane domain and the CRD [18].
Cleavage at this site results in secretion of the CRD as a
soluble protein [18, 19]. Isoforms b and d lack this signal
therefore they are not proteolytically cleaved but rather
remain membrane bound where they may oligomerize with
ASGR1 isoform a to form native ASGPR at the cell surface.
The secreted forms of ASGR1 and ASGR2 are able to
associate into soluble ASGPR [17, 19]. There is evidence
to suggest that the soluble receptor may bind free sub-
strates in the circulation and carry them to the liver for
uptake and degradation [17]. Aside from membrane attach-
ment/secretion, it is not known whether further functional
variation, such as, substrate specificity, may be associated
with the diﬀerent isoforms of ASGR1 and ASGR2.
Based on the observation above that the ASGPR is
expressed in rat peritoneal macrophages, it was considered
possible that monocytes, the lineage precursor of tissue
macrophages, may also express the receptor. To the best
of our knowledge, this has not been reported in human
monocytes. The present study investigated the expression of
ASGR1 and ASGR2 in human peripheral blood monocytes.
The data showed that both ASGR1 and ASGR2 are expressed
in human monocytes in the circulation, that expression
cannot be detected in lymphocytes and granulocytes, that the
transcripts of both genes diﬀer between individuals and that,
in a given individual, the transcription profile for ASGR2 is
restricted to one of two patterns. The findings are of potential
importance for health and disease in a variety of disciplines.
2. Design and Methods
2.1. Nomenclature. Genes, transcripts, and proteins are
referred to by their formal scientific names as listed in
the National Centre for Biotechnology Information (NCBI)
[20], which complies with standardized international
nomenclature. Table 1 provides a comparison with alterna-
tive names widely used in ASGPR literature. Gene sizes, exon
numbering, and so forth were obtained from the reference
sequences listed in Table 1.
2.2. Blood Samples. EDTA-anticoagulated whole blood in
excess of that required for routine blood tests was anon-
ymized and handled in accordance with Medical Research
Council guidelines [21]. The study was reviewed by the
local research ethics committee. All samples had normal
haematological parameters.
2.3. Separation of White Blood Cells
2.3.1. Stage 1. Depletion of platelets. Citrate- or EDTA-anti-
coagulated whole blood (5mL) was centrifuged at 200× g
for 10 minutes, ambient temperature to prepare platelet-rich
plasma (PRP). Two-thirds of the volume of the PRP was
carefully removed from above the buﬀy coat, centrifuged at
1800× g for 10 minutes to pellet the platelets, and then the
supernatant plasma returned to the original blood sample.
This process was repeated three times.
2.3.2. Stage 2. Separation of cells. After the depletion of
platelets as described above, the blood sample was loaded
onto a discontinuous Histopaque (Sigma Aldrich, Dorset,
UK) gradient comprising Histopaque 1119 (2mL, lower
layer) and Histopaque 1077 (3mL, upper layer). Following
centrifugation at 800× g for 1 h at ambient temperature, the
cells at the interface between the plasma and Histopaque
1077 (monocytes and lymphocytes) were harvested; the cells
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Table 1: ASGR1 and ASGR2 nomenclature and reference sequences.
Gene and transcript
(NCBI)
Protein and isoform
(NCBI)
Protein and isoform
alternative name
Gene and transcript reference
sequences (NCBI)
Protein and isoform reference
sequences (NCBI)
ASGR1 ASGR1 H1 AC 000060.1 not applicable
T1 a H1a NM 001671.4 NP 001662.1
T2 b H1b NM 001197216.2 NP 001184145.1
ASGR2 ASGR2 H2
T1 a H2a NG 029064.1 not applicable
T2 b H2c (L-H2) NM 001181.4 NP 001172.1
T3 c None NM 080913.3 NP 550435.1
T4 d H2b NM 080914.2 NP 550436.1
TH2′ a H2a NM 001201352.1NM 080912.3 NP 001188281.1NP 001172.1
NCBI abbreviates National Centre for Biotechnology Information [20].
at the interface between Histopaque 1077 and 1119 (princi-
pally granulocytes with a small proportion of lymphocytes)
were also harvested.
Harvested cells were washed by resuspension in 10mL
phosphate buﬀered saline pH 7.2 (PBS) followed by cen-
trifugation at 250× g for 10 minutes at ambient temperature.
The cell pellet was resuspended in PBS (0.7mL) and an
aliquot (0.2mL) was diluted 1 : 1 (v/v) with PBS and used for
determination of cell counts on a Pentra 120 (Horiba ABX,
Montpellier, France).
2.4. Cell Sorting Using Flow Cytometry. Citrate- or EDTA-
anticoagulated whole blood (5mL) was depleted of platelets
as described above (Separation of White Blood Cells). The
blood sample (3mL) was then loaded onto Histopaque 1077
(3mL) and centrifuged to separate the white blood cells
(WBC) (400× g, 30min, ambient temperature). The WBC
interface was harvested, washed, and an aliquot used for
determination of cell counts as described above (Separation
of White Blood Cells).
The remaining cells, suspended in PBS, were separated
according to forward scatter and side scatter light character-
istics using a MoFlo high speed cell sorter (Beckman Coulter,
High Wycombe, Bucks, UK). Gating was restrictive rather
than permissive: each gate was set only for the core popu-
lation of cells that had the required scatter characteristics.
In particular, the lymphocyte gate was set to minimise the
possibility of small monocytes being harvested. Purity checks
were subsequently performed by reanalysis of aliquots of
the sorted cells in the flow cytometer; purity was typically
around 98%.
2.5. Cell Culture. All reagents and consumables for cell cul-
ture were supplied by Invitrogen Life Technologies Ltd,
Paisley, Ireland. HepG2 (human hepatocyte carcinoma)
[22] and THP1 (human acute monocytic leukemia) [23]
cells were cultured in RPMI1640 medium + L-Glutamine,
supplemented with 10% (v/v) fetal calf serum and containing
penicillin (50 units/mL) and streptomycin (50 μg/mL). Cells
were grown at 37◦C in water-saturated air (95%, v/v), CO2
(5%, v/v) in 25 cm2 flasks. HepG2 cells (adherent cell line)
were liberated from the flask wall mechanically using a plastic
scraper and were separated by exposure to shear force. THP1
cells (nonadherent) were harvested directly from the culture
medium. Cells were counted using FastRead 10 disposable
hemocytometers (Immune Systems, UK). HepG2 has been
shown by others to express high levels of the Ashwell receptor
[24] and was used as a positive control in all relevant
experiments.
2.6. RNA Extraction and Reverse Transcription. RNA was
extracted using RNeasy kits (Qiagen, West Sussex, UK)
according to the manufacturer’s instructions. Yield was
determined spectrophotometrically and then 1.0 μg was
reverse transcribed into cDNA using random hexamers and
the High Capacity cDNA Reverse Transcription kit (Life
Technologies Ltd/Applied Biosystems, Paisley, UK) according
to the manufacturer’s instructions.
2.7. Polymerase Chain Reaction. Standard polymerase chain
reactions (PCRs) typically contained approximately 30 ng
cDNA in a mixture of dNTPs (100 μmol/L each), Tris-
HCl pH8.0 (10mmol/L), MgCl2 (1.5mmol/L), Taq DNA
polymerase (1U) (Applied Biosystems, Warwickshire, UK),
and primers (Figure 1) in a final volume of 25 μL. All primers
were used at 0.5 μmol/L. PCR was done using a 2720 DNA
Thermal Cycler (Applied Biosystems, Warwickshire, UK).
The primer sequences (5′ to 3′) were as follows:
ASG1RTF gaaagatgaagtcgctagagt
ASG1RTR aggctccgcaggtcagacac
A1CDSF1 gtagcgcgacggccagtactgaagaacctgggaatcagac
A1CDSR1 cagggcgcagcgatgacagctcctcaccttcggaacatca
A1TEST2 gaccaaggagtatcaagacctt
ASG2RTF cacacctggtggtcatcaac
ASG2RTR aattatctggctgagtgacag
ASGR2RTF3 agctgagctcggaggaaaatg
ASGR2RTR2 gcagctcggcttgcagctgtg
A2CDSF1 gtagcgcgacggccagtcccagccctcagagcaacctca
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A2CDSR1 cagggcgcagcgatgactcaacagagaagccagagctg-
gg
B2MRTF tccgtggccttagctgtgct
B2MRTR ccagtccttgctgaaagaca
N13F gtagcgcgacggccagt
N13R cagggcgcagcgatgac
Primers were designed for RT-PCR according to the
following criteria: (1) they flanked at least one intron; (2)
they were specific for ASGR1 or ASGR2 transcripts, cross
hybridization was not possible despite the sequence homol-
ogy between the coding sequences of the two genes. N13F
and N13R are, respectively, modified M13 universal and
reverse sequencing primers as previously described [25].
Underlined nucleotides are not part of ASGR1 or ASGR2
sequence but are tails corresponding to N13F or N13R to
facilitate sequence analysis.
For nested PCR, first-round synthesis was as above. The
first-round product was then diluted 10-fold with water and
1 μL of diluent was used as the substrate in the second round
of PCR.
PCR conditions were as follows:
Standard PCR: 94◦C for 30 s; 60◦C for 30 s; 72◦C for
1min.
Nested PCR: 1st round 94◦C for 30 s; 60◦C for 30 s;
72◦C for 1min 30 s.
Nested PCR: 2nd round 94◦C for 30 s; 60◦C for 30 s;
72◦C for 1min.
Routinely, 30 cycles of amplification were used; however, for
real time PCR, 55 cycles were employed.
2.8. Real-Time Quantitative PCR. ASGR1 and ASGR2 tran-
script levels were measured using LightCycler FastStart DNA
Master SYBR Green I (Roche Products Ltd, Hertfordshire,
UK) according to the manufacturer’s instructions, with
3mmol/L MgCl2 final concentration in the reaction. Reac-
tions contained 2 ng cDNA per 20 μL and relevant primers
(Figure 1). Primers were used at 0.5 μmol/L. Analyses were
done in duplicate in a LightCycler II using LightCycler v4.0
software (Perkin Elmer-Applied Biosystems, Warwickshire,
UK) using the following conditions: 94◦C for 10min fol-
lowed by 55 cycles comprising 94◦C for 10 s; 64◦C for 5 s;
72◦C for 10 s.
2.9. Nucleotide Sequence Analysis. PCR products were puri-
fied using the HighPure kit (Boehringer Mannheim, Not-
tingham, UK) and then sequenced using BigDye3.1 accord-
ing the manufacturer’s instructions (Perkin Elmer-Applied
Biosystems, Warrington, UK). Sequencing primers were
either the 5′ PCR primer, 3′ PCR primer, N13F or
N13R according to the amplification product. Sequenc-
ing reaction products were purified using QIAquick PCR
purification columns (Qiagen, West Sussex, UK) and then
electrophoresed on an Applied Biosystems 3130XL Genetic
analyser.
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Figure 1: ASGR1 and ASGR2 transcripts and encoded protein
isoforms. (a) ASGR1. (b) ASGR2. In both panels solid lines indicate
nucleotide sequence that is present in a transcript, grey boxes
represent coding sequence, dotted lines indicate sequence that is
not present in a transcript. Arrows indicate location and direction
of primers used in RT-PCR. Data for transcripts and isoforms are
taken from NCBI [14, 15].
2.10. Gel Electrophoresis of PCR Products. Agarose gel elec-
trophoresis: the analyses used 2% (w/v) gels and 1x TBE
buﬀer (tris (90mmol/L), boric acid (90mmol/L), EDTA
(1.25mmol/L), pH 8.0); visualization was done using ethid-
ium bromide staining and UV light.
Polyacrylamide gel electrophoresis: gels comprised poly-
acrylamide (total acrylamide = 5%, w/v; cross link = 3.3%,
w/v) and 1x TBE buﬀer, visualization was done using silver
staining [26].
The DNA size standard pBR322/MspI (New England Bio-
labs, Hertfordshire, UK) was used for all electrophoretic
analyses.
3. Results
3.1. ASGR1 and ASGR2 Are Expressed in Peripheral Blood
Monocytes. Initially, peripheral blood mononuclear cells
(PBMCs) were harvested and screened for ASGR1 and
ASGR2 expression without fractionation into monocytes/
lymphocytes/granulocytes. RT-PCR of RNA extracted from
PBMCs demonstrated the presence of both ASGR1 and
ASGR2 transcripts (Figure 2(a)). These were also detected in
the monocyte cell line THP1 (Figure 2(a)).
Following these initial findings, PBMCs were fraction-
ated in order to localize the cells in which ASGR1 and ASGR2
expression was present. Histopaque gradients allowed sepa-
ration of cells into monocytes + lymphocytes (M + L) and
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Figure 2: Detection of ASGR1 and ASGR2 transcripts in peripheral blood mononuclear cells and localization to monocytes. Transcripts
were detected using RT-PCR, the presence of ASGR1 transcripts was indicated by a 113 bp amplification product (primers ASG1RTF +
ASG1RTR) and ASGR2 transcripts by a 171 bp product (primers ASG2RTF + ASG2RTR). HepG2 was used as a positive control and water
as a negative control. Where necessary, β-2-microglobulin (B2M) was used as a reference to demonstrate equivalent amplification for each
RNA preparation, (primers B2MRTF + B2MRTR, product 231 bp). (a) Analysis of RNA from monocyte cell line THP1 and PBMCs from
two unrelated individuals (1 and 2). ASGR1 and ASGR2 transcripts were detected in all cases. (b) Analysis of RNA from peripheral blood
cell fractions: monocytes + lymphocytes (M + L) and granulocytes + lymphocytes (G + L). ASGR1 and ASGR2 transcripts were detected in
M + L but not in G + L. (c) Analysis of RNA from cell-sorted monocytes (mono, lanes 1–3 triplicate analyses) and lymphocytes (lymph,
lanes 1–3 triplicate analyses) (data for water control not shown for ASGR1 and ASGR2). The data were obtained from a single experiment
involving several gels: these are indicated by separate gel windows. For each panel, analysis was done using agarose gel electrophoresis with
pBR322/MspI size standard (“Marker”, 238 bp and 120 bp indicated).
granulocytes + lymphocytes (G + L). These cell preparations
typically contained 10% monocytes/90% lymphocytes (M +
L) and 94% granulocytes/10% lymphocytes (G + L) (data
not shown).
Using RT-PCR, ASGR1 and ASGR2 transcripts were
detected in RNA from the M + L fraction but not in
RNA from the G + L fraction (Figure 2(b)). These findings
were reproducible for blood samples taken from 3 diﬀerent
individuals (data not shown). The G + L fraction did not
yield a product for the transcripts even after 50 cycles of RT-
PCR amplification (Figure 2(b)). Some nonspecific products
were obtained as a result of this high number of cycles;
however, these did not interfere with the main result of the
experiment (Figure 2(b)).
Because lymphocytes were common to both cell frac-
tions, and because the G + L fraction was reproducibly neg-
ative for ASGR1 and ASGR2 transcripts, the data suggested
that expression of the two genes was localized to monocytes.
To confirm this, monocytes and lymphocytes were formally
cell sorted using flow cytometry, RNA extracted and screened
using RT-PCR. Monocytes gave a positive result for both
ASGR1 and ASGR2 transcripts, whilst lymphocytes did not
give a PCR product, even after 50 cycles of amplification
(Figure 2(c)). This high cycle number resulted in the burst-
through of some nonspecific products; however, these did
not interfere with the interpretation (Figure 2(c)). These data
provide strong evidence for expression of ASGR1 and ASGR2
in monocytes but not in lymphocytes or granulocytes.
3.2. Monocyte ASGR1 Transcripts Diﬀer between Individuals.
Two transcripts have been described for ASGR1 [17].
The longer transcript (T1) encodes isoform a (full-length
ASGR1), the shorter transcript (T2) has an in-frame deletion
of 117 nucleotides in the coding sequence resulting in a
shorter isoform (isoform b) (Figure 1(a)). The latter lacks the
transmembrane domain and is secreted as a soluble protein.
In the liver, T1 has been shown to be the predominant
isoform, with very little T2 detectable [17]. Using a nested
PCR approach to screen RNA from the M+L cell fraction of
peripheral blood, diﬀerent individuals showed the presence
of either T1 or of both T1 and T2 (Figure 3). Among
the five individuals screened, none showed the presence of
transcript T2 on its own. In combination with the data in
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Figure 3: ASGR1 transcript profiles in diﬀerent individuals. Nested
PCR was used to detect ASGR1 transcripts T1 and T2 (first
round primers A1CDSF1 + A1CDSR1; second round A1TEST2 +
ASG1RTR). A product of 408 bp represented T1, present in RNA
from the M + L cell fraction of five individuals (A–E) and also
in HepG2 and THP1; a 291 bp product indicated the presence
of T2 (individual E, and, very faintly, in HepG2). The RT-PCR
product for individual A was coloaded with the DNA size standard
(pBR322/MspI, 238 bp and 120 bp sizes indicated). Analysis was
done using agarose gel electrophoresis. The figure is a composite
of various data (indicated by individual gel windows).
Figure 2 (which showed that ASGR1 transcripts are detected
in monocytes and not lymphocytes), these data suggest
that the monocyte transcription profile for ASGR1 diﬀers
between individuals. THP1 gave a result consistent with the
presence of T1 (Figure 3).
3.3. Monocyte ASGR2 Transcripts Diﬀer between Individuals.
Five transcripts have been described for ASGR2, giving rise
to four protein isoforms (Figure 1(b)) [15]. Using a RT-PCR
designed to detect transcripts encoding diﬀerent isoforms,
the product profiles obtained for RNA extracted from the
Histopaque M + L cell fraction diﬀered among individuals.
Two distinct profiles were obtained, the first corresponded
to transcripts encoding isoforms a, b, c, and d, the second
to transcripts encoding isoforms b and d only (Figure 4).
ASGR2 isoforms a and c can give rise to soluble protein
via proteolysis between the transmembrane domain and
the CRD [18]. Isoforms b and d lack the proteolysis site
and cannot produce the soluble form. The data therefore
indicate that in some individuals, monocytes may produce
both soluble and membrane-bound ASGR2, whilst in others,
the soluble form is not produced by these cells.
3.4. Real-Time Quantitative PCR. Real-time PCR was opti-
mized for primer pairs ASG1RTF + ASG1RTR, ASG2RTF +
ASG2RTR (which, respectively, amplify all ASGR1 and
all ASGR2 transcripts) and B2MRTF + B2MRTR (which
amplify the reference target gene, B2M). For each primer
pair, a specific product was obtained that had a characteristic
melting curve (Figure 5).
Following PCR optimization, transcripts were measured
using relative quantification, in which the target was ASGR1
or ASGR2, the reference was B2M, the calibrator was HepG2,
and the unknown was flow sorted monocytes or THP1. B2M
is a recommended reference target for quantitative PCR,
having the advantages of a single transcript, no processed
pseudogene and expression at similar levels in a wide range
of tissues [27]. Flow-sorted monocytes and THP1 cells gave
similar results: relative to expression in HepG2, ASGR1
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Figure 4: ASGR2 transcript profiles in diﬀerent individuals.
Primer pair ASGR2RTF3 + ASGR2RTR2 gave RT-PCR products
of diﬀerent length (arrowed) according to the ASGR2 transcripts
present. RNA extracted from the M + L cell fraction of 6 diﬀerent
individuals (A–F) gave either a profile consistent with transcripts
encoding all isoforms (a, b, c, and d) or just with isoforms b and
d. The liver cell line HepG2 showed all transcripts, the monocyte
cell line THP1 showed only transcripts encoding isoforms b and
d. The analysis was done using polyacrylamide gel electrophoresis.
DNA size reference was pBR322/MspI (“Marker”, 238 bp and 120 bp
sizes indicated). In addition to the expected products, additional
major bands were visualized on polyacrylamide gel electrophoresis
of the RT-PCR screen for ASGR2 transcripts (bracketed bands).
It was considered possible that these represented heteroduplexes
arising by cross-hybridization of complementary strands of the
closely homologous true PCR products. To test this, each candidate
heteroduplex band was excised from the gel, eluted into water,
reamplified using the primers used in the initial PCR and the
products electrophoresed on polyacrylamide. The results confirmed
that the additional bands were hybrid duplexes containing comple-
mentary strands from nonidentical true PCR products: each hybrid
yielded products consistent with amplification of two diﬀerent
template strands (data not shown).
transcripts were between 1.53E-07 to 7.53E-06-fold less,
whilst ASGR2 transcripts were between 7.16E-05 and 3.78E-
04-fold less. Figure 5 illustrates relative quantification of
ASGR1 and ASGR2 transcripts in cell-sorted monocytes. The
ratio of expression of ASGR1 :ASGR2 in monocytes and the
monocyte cell line THP1 was approximately 1 : 100.
3.5. Nucleotide Sequence Analysis. To ascertain whether
THP1 would be a suitable cell line for future ASGPR studies
in monocytes, the coding sequences of the ASGR1 and
ASGR2 transcripts produced by these cells were determined.
A nested PCR strategy was used as follows: the first round
of synthesis amplified the entire coding sequence plus some
5′ and 3′ flanking sequence and then second round PCRs
amplified nested portions within the first round product.
The nested portions were sequenced in both directions. For
ASGR2, one of the nested portions contained the region
that diﬀered between transcripts and gave products of
diﬀerent size according to the transcript. These products
were electrophoresed, excised from the gel, reamplified
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Figure 5: Real-time PCR analyses. (a) Agarose gel electrophoresis of products from optimized real-time PCRs for ASGR1 (113 bp, primers
ASG1RTF + ASG1RTR), ASGR2 (171 bp, primers ASG2RTF + ASG2RTR), and B2M (231 bp, primers B2MRTF + B2MRTR). Substrate
was HepG2 cDNA. (b) Melting curve analysis of real-time PCR products from panel (a). The Tm for each product is indicated. (c and d)
Relative quantification of ASGR1 (c) and ASGR2 (d) transcripts in cell-sorted monocytes (MC) compared with HepG2 (G2). B2M was
used as the reference. (i) Fluorescence profiles obtained during real-time PCR. Samples were analyzed in duplicate, for clarity only one of
each duplicate is shown. (ii) Melting curve analysis for the real-time PCR products in (i). (iii) Agarose gel electrophoresis of real-time PCR
products (duplicate analyses shown). Neg indicates real-time PCR control containing water instead of nucleic acid template. In panels a,
c(iii), and d(iii), M denotes pBR322/MspI size standard (238 bp and 120 bp sizes indicated).
individually, and then sequenced, to give the sequence of
each of the coding regions that diﬀered between transcripts.
THP1 ASGR1 and ASGR2 transcripts corresponded with
previously described splice variants found in the liver (data
not shown). The findings demonstrate that THP1 cells have
the capacity to transcribe and process correctly, transcripts
encoding functional isoforms of the ASGPR. Taken together
with the results in Figures 3 and 4, the data provide evidence
that monocytes express correctly processed transcripts from
both ASGR1 and ASGR2 and thereby have the potential to
produce functional ASGPR.
The coding sequence for ASGR1 in THP1 diﬀered from
the NCBI reference sequence (Table 1) by a single nucleotide:
c.267G>A, for which the monocyte cell line was homozygous
(data not shown). This change is silent at the protein level
(codon 89, AAG, changes to AAA, both encoding lysine). The
change is a naturally occurring variant (rs55714927) listed
in the international SNP database (dbSNP) [28]. The THP1
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ASGR2 coding sequence for any transcript did not diﬀer to
the corresponding NCBI reference sequence (Table 1) (data
not shown).
4. Discussion
In this study, expression of ASGR1 and ASGR2 was demon-
strated in peripheral blood monocytes. For both genes,
transcript profiles were obtained that corresponded with
known splice variants found in the liver. To the best of
our knowledge, this is the first report of the expression
of correctly processed transcripts of ASGR1 and ASGR2
by human monocytes. In rat, a transcript encoding an
asialoglycoprotein-binding protein was isolated from a peri-
toneal macrophage cDNA library and was highly homolo-
gous to that of the rodent hepatic ASGPR [5]. The data
were interpreted to indicate that the rodent macrophage
asialoglycoprotein-binding protein and the liver ASGPRwere
encoded by related genes [5]; however, it now seems possible
that alternative splicing may underlie the diﬀerences. The
findings of the present study do not suggest expression of
alternative ASGPR-related genes in monocytes, rather they
are entirely consistent with transcription of ASGR1 and
ASGR2, as occurs in the liver.
The various transcripts of ASGR1 and ASGR2 encode
diﬀerent isoforms of the proteins (Figure 1). It is not
known whether the isoforms diﬀer in their specificity or
functionality, however it is predicted that certain isoforms
have the potential to give rise to soluble forms of each
protein. ASGR1 transcript T2 has an in-frame deletion of
117 bp that encode the transmembrane domain; the resulting
isoform “b” therefore is soluble and secreted [17]. ASGR2
transcripts T1, TH2′ and T3 encode isoforms “a” (T1 and
TH2’) and “c” (T3) which contain a proteolysis signal that,
upon cleavage, gives rise to soluble protein [18]. Transcripts
T2 and T4, respectively, encode isoforms b and d which
lack the proteolysis signal and are membrane bound. The
data presented here indicate that monocytes are able to
express transcripts encoding soluble and membrane-bound
isoforms of the ASGPR proteins. ASGR2 was found to give
rise to two transcript profiles, only one of which was present
in the monocytes from any given individual. One profile
corresponded with transcripts encoding both soluble and
membrane-bound ASGR2 isoforms (a, b, c, and d), the other
with membrane-bound ASGR2 isoforms (b and d) only. This
novel finding indicates a fundamental diﬀerence between
individuals. The underlying basis for this and whether or
not it has physiologic significance in health or disease merit
further exploration.
The level of ASGR1 and ASGR2 expression was consid-
erably less in monocytes and the monocyte cell line THP1
compared with the liver cell line HepG2. It should be borne
in mind that HepG2 expresses high levels of the receptor
[24] and the monocyte expression was relative to this. That
monocyte transcripts were not rare within the cells was
indicated by the fact that they were readily detected using RT-
PCR at routine cycle numbers. Low level of expression of the
ASGPR has been reported previously in certain nonhepatic
tissues (rat macrophages [5], human intestinal epithelial cells
[6], mouse testis [7], and rat thyroid gland [8]). It would be
relevant to explore whether ASGR1 and ASGR2 transcription
alters upon monocyte activation.
The relative expression of ASGR1 and ASGR2 in mono-
cytes and THP1 (1 : 100) diﬀered notably from ratios
reported in liver (1 : 2 [1] and 1 : 6 [16]). The diﬀerence may
be real, or it may reflect diﬀerences in methodology between
studies or possibly a diﬀerence in the amplification eﬃciency
of the primer pair used for ASGR1 compared with that used
for ASGR2. The true relative expression of the two genes by
monocytes therefore remains to be established.
An important question arising from these results is
whether monocytes translate ASGR1 and ASGR2 transcripts
and produce functional ASGPR. The restricted expression of
the genes in monocytes, but not in lymphocytes or granulo-
cytes, suggests the transcripts are not produced randomly but
specifically. Based on the fundamental principles of biology,
this is likely to be for translation, it is diﬃcult to think why
else diﬀerent transcripts encoding diﬀerent isoforms may be
produced by one specific cell type in the blood. The restricted
tissue specificity for ASGPR expression in the body, and the
lower expression level observed at the nonhepatic locations,
could signal a specific role or function at those sites. In the
case of monocytes, the receptor could, at the very least, serve
a scavenger function where there is infection or tissue injury.
Expression of correctly processed transcripts of ASGR1
and ASGR2 by circulating monocytes has potentially sig-
nificant implications in several important areas. These can
be grouped into two main themes: normal physiology and
drug design. If monocytes express functional ASGPR, they
may contribute towards the normal physiological processes
undertaken by the hepatocyte receptor. Whilst hepatocyte
ASGPR is localized to the liver and relies upon the cir-
culation to deliver ligands to it, the monocyte receptor
would represent a mobile pool that can reach ligands in
most parts of the body. Monocyte ASGPR may additionally
interact with ligands in the blood, as does liver ASGPR.
Thus, the monocyte receptor, if it is produced, may overlap
functionally with that of the liver but may have additional
physiological roles elsewhere in the body.
Hepatic ASGPR has been shown to be directly involved
in the normal turnover of an important protein of primary
hemostasis, VWF. Studies in knock-out mice indicated that
the ASGPR is engaged in the constitutive control of VWF
level and can, additionally, remove hemostatic components
(VWF and platelets) desialylated by bacterial neuraminidase,
a possible survival mechanism in disseminated intravascular
coagulation [3]. The results in these studies were ascribed
to the activity of the liver receptor; however, our data raise
the possibility that monocytes may contribute to the relevant
physiological processes via the ASGPR.
The findings have implications for the design of drugs
targeting the liver via the ASGPR and drugs that are cleared
by this receptor [29, 30]. Various strategies have been used,
for example, conjugation of drug with galactosyl terminating
molecules, as has been done with antiviral nucleoside
analogues in the treatment of chronic viral hepatitis [31].
Besides drug targeting, strategies to deliver genes or other
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nucleic acids to the liver have also made use of the ASGPR
[10–12]. Relatively recently, successful in vivo delivery of
siRNAs to the liver in mice has been achieved via simple
intravenous injection employing ASGPR-specific conjugates
containing GalNAc [11]. Pharmacological targeting of the
ASGPR could not be considered to be predominantly liver-
specific if monocytes express the receptor.
5. Conclusions
ASGR1 and ASGR2 are expressed in peripheral blood mono-
cytes in humans. For both genes, monocytes have the ability
to produce correctly spliced transcripts encoding each of the
known protein isoforms. However, there are interindividual
diﬀerences in the transcript profiles; of particular note,
despite several possible ASGR2 transcripts, just two combi-
nations were found to occur. This observation indicates that,
in any given individual, ASGR2 mRNA splicing is restricted
to one of two profiles. Quantitative studies indicate that
expression of both ASGR1 and ASGR2 is lower in monocytes
than in the liver, but none-the-less is readily detected in
monocytes (in comparison to other blood cells in which
expression could not be demonstrated). The liver may rep-
resent a static site to which blood carries glycoconjugates for
ASGPR-mediated removal, whilst monocytes may represent
a mobile pool that can reach sites where the activity of the
receptor is needed.
The data presented here open various important avenues
for future research, a notable one of which is the mea-
surement and characterization of monocyte ASGPR protein.
The results for the cell line THP1 indicated it could be
used as a model system for the investigation of monocyte
ASPGR function and activity. Monocytes play a pivotal
role in inflammation and immunity, the finding of ASGPR
transcripts within these cells oﬀers new insight into their
biochemistry and functional potential.
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